Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: aerovatetx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | $27.00 → $2.00 | Outperform → In-line | Evercore ISI |
| 6/18/2024 | Buy → Hold | TD Cowen | |
| 6/18/2024 | $35.00 → $2.00 | Overweight → Equal Weight | Wells Fargo |
| 6/17/2024 | Buy → Neutral | Guggenheim | |
| 6/17/2024 | Buy → Neutral | BTIG Research | |
| 6/17/2024 | $41.00 → $3.00 | Outperform → Neutral | Wedbush |
| 3/25/2024 | $21.00 → $65.00 | Buy | Jefferies |
| 12/8/2023 | $35.00 | Equal Weight | Wells Fargo |
| 3/1/2023 | $36.00 | Buy | Guggenheim |
| 12/6/2022 | $27.00 | Neutral → Buy | BTIG Research |
4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)